First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study - PubMed

Merck & Co.
www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov